To include your compound in the COVID-19 Resource Center, submit it here.

Celgene beats Street

Celgene Corp. (NASDAQ:CELG) reported 2Q11 non-GAAP diluted EPS of $0.89, beating

Read the full 110 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE